CUBE vs IKT · P/E 25, rev $1.07B vs $215.2M cap
CubeSmart (CUBE) versus Inhibikase Therapeutics Inc (IKT) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported IKT revenue for 2024-12-31 was $0. Net income was -$27.5M. Revenue was down 100.0% from 2023-12-31 to 2024-12-31. IKT currently screens at market cap $215.2M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. IKT currently screens at market cap $215.2M.
Not investment advice. Open the CUBE and IKT stock pages for the full models.
Not investment advice.